|
LOC402377 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.71456207407073E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.7506000789308E-12 |
| Normal-vs-Stage2 |
5.59149999967978E-07 |
| Normal-vs-Stage3 |
2.48512321832095E-12 |
| Normal-vs-Stage4 |
1.62836411021772E-12 |
| Stage1-vs-Stage2 |
1.901980E-01 |
| Stage1-vs-Stage3 |
4.982200E-01 |
| Stage1-vs-Stage4 |
4.552900E-04 |
| Stage2-vs-Stage3 |
1.073400E-01 |
| Stage2-vs-Stage4 |
2.322900E-03 |
| Stage3-vs-Stage4 |
1.299880E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.84490225716172E-12 |
| Normal-vs-AfricanAmerican |
3.21430004834866E-09 |
| Normal-vs-Asian |
2.59825494453025E-12 |
| Caucasian-vs-AfricanAmerican |
8.126400E-01 |
| Caucasian-vs-Asian |
1.744950E-01 |
| AfricanAmerican-vs-Asian |
4.932200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.42819131257966E-13 |
| Normal-vs-Female |
9.09694541917361E-12 |
| Male-vs-Female |
1.408200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.0019984841847E-11 |
| Normal-vs-Age(41-60Yrs) |
5.28843635549947E-12 |
| Normal-vs-Age(61-80Yrs) |
8.8902218919884E-12 |
| Normal-vs-Age(81-100Yrs) |
4.563600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.475400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.112600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.596600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.154000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.931000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.911600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.555710E-02 |
| Classical-VS-Follicular |
2.385400E-01 |
| Classical-VS-Other |
1.617210E-01 |
| Classical-VS-Normal |
1.27500232594002E-11 |
| Tall-VS-Follicular |
5.259700E-03 |
| Tall-VS-Other |
5.621400E-01 |
| Tall-VS-Normal |
1.81954451505817E-12 |
| Follicular-VS-Other |
1.277440E-01 |
| Follicular-VS-Normal |
2.18469997648185E-09 |
| Other-VS-Normal |
1.10590000046429E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.88390455749754E-11 |
| Normal-vs-N1 |
1.63691282750733E-12 |
| N0-vs-N1 |
1.803670E-03 |
|
|
